186-OR: Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM)

RICCARDO PERFETTI; FRANCESCA C. LAWSON; JULIO ROSENSTOCK; JAMES JANUZZI; SHOSHANA SHENDELMAN; STELLA WANG; AMEEN F. GHANNAM

doi:10.2337/db20-186-OR

Oral Presentations: Clinical Diabetes/Therapeutics

186-OR: Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM)

RICCARDO PERFETTI,
FRANCESCA C. LAWSON,
JULIO ROSENSTOCK,
JAMES JANUZZI JR.,
SHOSHANA SHENDELMAN,
STELLA WANG and
AMEEN F. GHANNAM

New York, NY, Dallas, TX, Wellesley Hills, MA

Diabetes 2020 Jun; 69(Supplement 1): -. https://doi.org/10.2337/db20-186-OR

Article Information

vol. 69 no. Supplement 1

DOI

https://doi.org/10.2337/db20-186-OR

Published By

American Diabetes Association

Print ISSN

0012-1797

Online ISSN

1939-327X

History

Published in print June 9, 2020.

© 2020 by the American Diabetes Association http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.